Nicholas J Hawkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3450850/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kirsten ras mutations in patients with colorectal cancer: the â€~RASCAL II' study. British Journal of Cancer, 2001, 85, 692-696.	6.4	790
2	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-3415.	7.1	425
3	Inheritance of a Cancer-Associated <i>MLH1</i> Germ-Line Epimutation. New England Journal of Medicine, 2007, 356, 697-705.	27.0	380
4	Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. Cancer Discovery, 2014, 4, 175-185.	9.4	359
5	CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 2002, 122, 1376-1387.	1.3	338
6	Sporadic Colorectal Cancers With Microsatellite Instability and Their Possible Origin in Hyperplastic Polyps and Serrated Adenomas. Journal of the National Cancer Institute, 2001, 93, 1307-1313.	6.3	318
7	Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut, 2001, 48, 821-829.	12.1	308
8	<i>SMAD2</i> , <i>SMAD3</i> and <i>SMAD4</i> Mutations in Colorectal Cancer. Cancer Research, 2013, 73, 725-735.	0.9	260
9	Whole slide images based cancer survival prediction using attention guided deep multiple instance learning networks. Medical Image Analysis, 2020, 65, 101789.	11.6	202
10	Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. Journal of Clinical Pathology, 2009, 62, 516-518.	2.0	180
11	MLH1 Germline Epimutations as a Factor in Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 2005, 129, 1392-1399.	1.3	179
12	Adverse Prognostic Effect of Methylation in Colorectal Cancer Is Reversed by Microsatellite Instability. Journal of Clinical Oncology, 2003, 21, 3729-3736.	1.6	178
13	The Relationship between Hypomethylation and CpG Island Methylation in Colorectal Neoplasia. American Journal of Pathology, 2003, 162, 1361-1371.	3.8	165
14	Colorectal cancer: a model for epigenetic tumorigenesis. Gut, 2007, 56, 140-148.	12.1	146
15	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. American Journal of Gastroenterology, 2013, 108, 1785-1793.	0.4	120
16	Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene, 2013, 32, 4675-4682.	5.9	117
17	<i>PIK3CA</i> and <i>PTEN</i> Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 3285-3296.	7.0	107
18	Does MSI-low exist?. Journal of Pathology, 2002, 197, 6-13.	4.5	95

#	Article	IF	CITATIONS
19	Developmentally-regulated expression of murine K-ras isoforms. Oncogene, 1997, 15, 1781-1786.	5.9	79
20	Restriction Endonuclease-Mediated Selective Polymerase Chain Reaction. American Journal of Pathology, 1998, 153, 373-379.	3.8	79
21	Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Research, 2002, 62, 53-7.	0.9	79
22	Population-Based Molecular Screening for Lynch Syndrome: Implications for Personalized Medicine. Journal of Clinical Oncology, 2013, 31, 2554-2562.	1.6	76
23	Histopathological and Clinical Evaluation of Serrated Adenomas of the Colon and Rectum. Modern Pathology, 2003, 16, 417-423.	5.5	74
24	CD103+ intraepithelial lymphocytes—a unique population in microsatellite unstable sporadic colorectal cancer. European Journal of Cancer, 2003, 39, 469-475.	2.8	74
25	Activation of the K-ras oncogene in colorectal neoplasms is Associated with decreased apoptosis. , 1997, 79, 1106-1113.		66
26	Colorectal Carcinomas Arising in the Hyperplastic Polyposis Syndrome Progress through the Chromosomal Instability Pathway. American Journal of Pathology, 2000, 157, 385-392.	3.8	65
27	Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. British Journal of Cancer, 2001, 84, 232-236.	6.4	65
28	Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Human Immunology, 1999, 60, 510-515.	2.4	64
29	MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Modern Pathology, 2009, 22, 1588-1599.	5.5	64
30	Epigenetic Inactivation of a Cluster of Genes Flanking <i>MLH1</i> in Microsatellite-Unstable Colorectal Cancer. Cancer Research, 2007, 67, 9107-9116.	0.9	63
31	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	8.1	60
32	Retrieval of human antibodies from phage-display libraries using enzymatic cleavage. Journal of Immunological Methods, 1996, 189, 73-82.	1.4	58
33	Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. Journal of Cancer Research and Clinical Oncology, 2015, 141, 243-254.	2.5	58
34	The serrated neoplasia pathway. Pathology, 2002, 34, 548-55.	0.6	58
35	<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 2018, 8, 988-1005.	9.4	55
36	Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 2019, 68, 465-474.	12.1	52

#	Article	IF	CITATIONS
37	The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. British Journal of Cancer, 2007, 96, 783-792.	6.4	50
38	RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. British Journal of Cancer, 2014, 110, 1606-1613.	6.4	50
39	Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. Journal of Pathology, 2005, 207, 377-384.	4.5	49
40	Implementation of Novel Pyrosequencing Assays to Screen for Common Mutations of BRAF and KRAS in a Cohort of Sporadic Colorectal Cancers. Diagnostic Molecular Pathology, 2009, 18, 62-71.	2.1	48
41	The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. British Journal of Cancer, 2006, 95, 1239-1243.	6.4	47
42	Biodistribution of filamentous phage-Fab in nude mice. Journal of Immunological Methods, 1999, 225, 171-178.	1.4	42
43	Epigenetic inactivation of the candidate tumor suppressor <i>USP44</i> is a frequent and early event in colorectal neoplasia. Epigenetics, 2014, 9, 1092-1100.	2.7	42
44	Cohesin Rad21 Mediates Loss of Heterozygosity and Is Upregulated via Wnt Promoting Transcriptional Dysregulation in Gastrointestinal Tumors. Cell Reports, 2014, 9, 1781-1797.	6.4	40
45	Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Modern Pathology, 2011, 24, 396-411.	5.5	39
46	Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. British Journal of Cancer, 2015, 113, 979-988.	6.4	35
47	Pathological and Genetic Correlates of Apoptosis in the Progression of Colorectal Neoplasia. Tumor Biology, 1997, 18, 146-156.	1.8	34
48	Isolation of human anti-c-erb B-2 Fabs from a lymph node-derived phage display library. Clinical and Experimental Immunology, 1997, 109, 166-174.	2.6	32
49	Detection of Rare Mutant Alleles by Restriction Endonuclease-mediated Selective-PCR: Assay Design and Optimization. Clinical Chemistry, 2000, 46, 620-624.	3.2	30
50	Editorial: progress in gastrointestinal pathology in the genetic era. Pathology, 2002, 34, 493.	0.6	29
51	ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration. BMC Cancer, 2016, 16, 508.	2.6	29
52	Adaptive Tutorials Versus Web-Based Resources in Radiology: A Mixed Methods Comparison of Efficacy and Student Engagement. Academic Radiology, 2015, 22, 1299-1307.	2.5	28
53	Evaluation of different lymphoid tissue sources for the construction of human immunoglobulin gene libraries. Immunotechnology: an International Journal of Immunological Engineering, 1997, 3, 195-203.	2.4	27
54	Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2002, 128, 403-411.	2.5	27

#	Article	IF	CITATIONS
55	The CpG Island Methylator Phenotype Is Not Associated with a Personal or Family History of Cancer. Cancer Research, 2004, 64, 7618-7621.	0.9	27
56	The role of mesangial cells in glomerular pathology. Pathology, 1990, 22, 24-32.	0.6	27
57	Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 757-762.	2.5	26
58	The Role of hMLH1 Methylation in the Development of Synchronous Sporadic Colorectal Carcinomas. Diseases of the Colon and Rectum, 2002, 45, 674-680.	1.3	26
59	Altered promoter nucleosome positioning is an early event in gene silencing. Epigenetics, 2014, 9, 1422-1430.	2.7	25
60	Biological Significance of Microsatellite Instability-Low (MSI-L) Status in Colorectal Tumors. American Journal of Pathology, 2001, 158, 779-781.	3.8	23
61	Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. Oncotarget, 2016, 7, 36474-36488.	1.8	23
62	SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i> -Methylated Colorectal Cancer. Clinical Cancer Research, 2016, 22, 6266-6277.	7.0	22
63	Detection of K-raspoint mutation by enriched PCR–colorimetric plate assay. Molecular and Cellular Probes, 1997, 11, 33-38.	2.1	21
64	Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. Molecular Cancer Research, 2016, 14, 1217-1228.	3.4	20
65	c-kit mutations in gastrointestinal stromal tumours. Pathology, 2002, 34, 315-319.	0.6	19
66	Relative Distribution of Folate Species Is Associated with Global DNA Methylation in Human Colorectal Mucosa. Cancer Prevention Research, 2012, 5, 921-929.	1.5	19
67	Inactivation ofp16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. Journal of Surgical Oncology, 2003, 84, 143-150.	1.7	18
68	Abstract 3125: Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosa. , 2012, , .		18
69	Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. Modern Pathology, 2020, 33, 1420-1432.	5.5	17
70	Detection of allelic imbalance in MLH1 expression by pyrosequencing serves as a tool for the identification of germline defects in Lynch syndrome. Familial Cancer, 2010, 9, 345-356.	1.9	14
71	Introducing Research Initiatives into Healthcare: What Do Doctors Think?. Biopreservation and Biobanking, 2014, 12, 91-98.	1.0	14
72	Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes and Cancer, 2015, 54, 303-314.	2.8	14

#	Article	IF	CITATIONS
73	Poor-Prognosis Estrogen Receptor–Positive Breast Cancer Identified by Histopathologic Subclassification. Clinical Cancer Research, 2008, 14, 6625-6633.	7.0	13
74	Selectable in-vivo recombination to increase antibody library size — an improved phage display vector system. Gene, 1999, 227, 49-54.	2.2	12
75	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. Oncologist, 2016, 21, 618-625.	3.7	12
76	Disruption of a â^'35 kb Enhancer Impairs CTCF Binding and <i>MLH1</i> Expression in Colorectal Cells. Clinical Cancer Research, 2018, 24, 4602-4611.	7.0	12
77	Regulation and expression of human Fabs under the control of the Escherichia coli arabinose promoter, PBAD. Immunotechnology: an International Journal of Immunological Engineering, 1997, 3, 217-226.	2.4	11
78	Germline epimutations of APC are not associated with inherited colorectal polyposis. Gut, 2006, 55, 586-587.	12.1	10
79	Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology, 2013, 45, 629-636.	0.6	10
80	A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. European Journal of Gastroenterology and Hepatology, 2013, 25, 319-326.	1.6	9
81	Unconjugated antibodies for cancer therapy: lessons from the clinic. Cancer Treatment Reviews, 1997, 23, 305-319.	7.7	8
82	Pathogenic germline MCM9 variants are rare in Australian Lynch-like syndrome patients. Cancer Genetics, 2016, 209, 497-500.	0.4	8
83	Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology, 2011, 43, 84-85.	0.6	7
84	Cytokine-Mediated Induction of HLA Antigen Expression on Human Glomerular Mesangial Cells. Cellular Immunology, 1994, 155, 493-500.	3.0	5
85	The null oncogene hypothesis and protection from cancer. Journal of Medical Genetics, 2002, 39, 12-14.	3.2	5
86	Re: Tomlinsonet al. Does MSI-low exist.J Pathol 2002; 197: 6-13. Journal of Pathology, 2003, 199, 267-269.	4.5	5
87	Activation of the Kâ€ras oncogene in colorectal neoplasms is Associated with decreased apoptosis. Cancer, 1997, 79, 1106-1113.	4.1	5
88	The Images of Disease Project: a computer-based aid to the teaching of pathology. Medical Teacher, 1997, 19, 45-50.	1.8	4
89	Factors Influencing the Detection of Mutant K-ras in the Serum of Patients with Colorectal Cancer. Annals of the New York Academy of Sciences, 2006, 906, 17-18.	3.8	3
90	Institutional biobanking: an integral part of contemporary pathology practice. Pathology, 2015, 47, 4-6.	0.6	2

#	Article	IF	CITATIONS
91	Scarcity of Recurrent Regulatory Driver Mutations in Colorectal Cancer Revealed by Targeted Deep Sequencing. JNCI Cancer Spectrum, 2019, 3, pkz012.	2.9	2
92	Biological Properties of Renal Oncocytoma Cells in Culture. Urologia Internationalis, 1996, 56, 69-74.	1.3	1
93	Checking the scoreboard: the impact of cancer genetics on clinical practice. Internal Medicine Journal, 2001, 31, 249-253.	0.8	1
94	Evaluation of the transferability of survival calculators for stage II/III colon cancer across healthcare systems. International Journal of Cancer, 2019, 145, 132-142.	5.1	1
95	Integration and Analysis of Heterogeneous Colorectal Cancer Data for Translational Research. Studies in Health Technology and Informatics, 2016, 225, 387-91.	0.3	1
96	Recombinant antibodies: back to the future. Australian and New Zealand Journal of Medicine, 1993, 23, 393-402.	0.5	0